Literature DB >> 4606368

Comparative trial of pancrex V forte and nutrizym in treatment of malabsorption in cystic fibrosis.

M C Goodchild, E Sagaró, G A Brown, P M Cruchley, H R Jukes, C M Anderson.   

Abstract

A cross-over trial of pancreatic enzyme replacement therapy has been conducted on 12 children with cystic fibrosis using Pancrex V forte and Nutrizym tablets in equivalent dosage. No differences were found in the effectiveness of these products as measured by stool volume, number of bowel actions, faecal fat excretion, and urine urea excretion. Neither product eliminated the steatorrhoea. Though there was no laboratory evidence to support their choice nine patients expressed a preference for Nutrizym at the conclusion of the trial. This preference was based partly on the smaller number of tablets which are required.

Entities:  

Mesh:

Substances:

Year:  1974        PMID: 4606368      PMCID: PMC1611844          DOI: 10.1136/bmj.3.5933.712

Source DB:  PubMed          Journal:  Br Med J        ISSN: 0007-1447


  6 in total

1.  "Break-through in cystic fibrosis".

Authors:  L W MATTHEWS; S SPECTOR
Journal:  Pediatrics       Date:  1961-03       Impact factor: 7.124

2.  A rapid and precise method for the determination of urea.

Authors:  J K FAWCETT; J E SCOTT
Journal:  J Clin Pathol       Date:  1960-03       Impact factor: 3.411

3.  The effect of pancreatin therapy on fat absorption and nitrogen retention in children with fibrocystic disease of the pancreas.

Authors:  R HARRIS; A P NORMAN; W W PAYNE
Journal:  Arch Dis Child       Date:  1955-10       Impact factor: 3.791

4.  Fat absorption studies in the diagnosis and treatment of pancreatic fibrosis.

Authors:  C A ROSS
Journal:  Arch Dis Child       Date:  1955-08       Impact factor: 3.791

5.  Coeliac disease; gastrointestinal studies and the effect of dietary wheat flour.

Authors:  C M ANDERSON; J M FRENCH; H G SAMMONS; A C FRAZER; J W GERRARD; J M SMELLIE
Journal:  Lancet       Date:  1952-04-26       Impact factor: 79.321

6.  Steatorrhea and azotorrhea and their relation to growth and nutrition in adolescents and young adults with cystic fibrosis.

Authors:  A Lapey; J Kattwinkel; P A Di Sant'Agnese; L Laster
Journal:  J Pediatr       Date:  1974-03       Impact factor: 4.406

  6 in total
  8 in total

Review 1.  Enzyme contents of pancreatic extract preparations. Are they optimal?

Authors:  S Maguire; M C Goodchild
Journal:  Drugs       Date:  1992-11       Impact factor: 9.546

2.  Study to compare the enzyme activity, acid resistance and dissolution characteristics of currently available pancreatic enzyme preparations.

Authors:  A M Whitehead
Journal:  Pharm Weekbl Sci       Date:  1988-02-19

3.  Critical examination of therapeutic efficacy of a pH-sensitive enteric-coated pancreatic enzyme preparation in treatment of exocrine pancreatic insufficiency secondary to cystic fibrosis.

Authors:  S K Dutta; V S Hubbard; M Appler
Journal:  Dig Dis Sci       Date:  1988-10       Impact factor: 3.199

4.  A comparison of enteric coated microspheres with enteric coated tablet pancreatic enzyme preparations in cystic fibrosis. A controlled study.

Authors:  H Vyas; D J Matthew; P J Milla
Journal:  Eur J Pediatr       Date:  1990-01       Impact factor: 3.183

5.  [Studies on the value of fecal tryptic and chymotryptic activity in the diagnosis and therapy of cystic fibrosis (author's transl)].

Authors:  J Weise; Y Kobayashi; W Tolckmitt
Journal:  Eur J Pediatr       Date:  1976-05-04       Impact factor: 3.183

6.  Vitamin status in treated patients with cystic fibrosis.

Authors:  P J Congden; G Bruce; M M Rothburn; P C Clarke; J M Littlewood; J Kelleher; M S Losowsky
Journal:  Arch Dis Child       Date:  1981-09       Impact factor: 3.791

7.  Effect of cimetidine and sodium bicarbonate on pancreatic replacement therapy in cystic fibrosis.

Authors:  P R Durie; L Bell; W Linton; M L Corey; G G Forstner
Journal:  Gut       Date:  1980-09       Impact factor: 23.059

8.  Pancreatic enzyme replacement therapy for people with cystic fibrosis.

Authors:  Usha Rani R Somaraju; Arturo Solis-Moya
Journal:  Cochrane Database Syst Rev       Date:  2020-08-05
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.